BrP-LPA (sodium)

BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA) . It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer[1].

Product Specifications

CAS Number

[944265-88-7]

UNSPSC

12352211

Target

LPL Receptor; Phosphodiesterase (PDE)

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Field of Research

Cancer

Smiles

O=P(O)(O[Na])C(Br)C[C@H](O)COC(CCCCCCCCCCCCCCC)=O

Molecular Formula

C20H39BrNaO6P

Molecular Weight

509.39

References & Citations

[1]Zhang H, et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69 (13) :5441-9.